Skip to main content

Table 2 Reductions in HPV-related disease incidence for routine plus catch-up 9-valent HPV (9vHPV) female-only vaccination (FOV) vs routine 9vHPV FOV, routine 9vHPV FOV vs screening, and routine plus catch-up 9vHPV FOV vs screening, over 100 years

From: The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong

HPV-related disease

Reduction in cases of HPV-related diseases n(%): Routine plus catch-upa 9vHPV vs routine 9vHPV

Reduction in cases of HPV-related disease n(%): Routine 9vHPV vs screening only

Reduction in cases of HPV-related disease n(%): Routine plus catch-Upa 9vHPV vs screening only

Cervical cancer

769 (3.4)

19,880 (46.9)

20,649 (48.7)

CIN 1

121 (4.9)

3968 (61.8)

4089 (63.7)

CIN 2/3

428 (4.6)

13,766 (59.7)

14,194 (61.5)

Vaginal cancer

2 (3.1)

48 (38.4)

50 (40.2)

Vaginal intraepithelial neoplasia 2/3

2 (3.4)

51 (43.6)

54 (45.5)

Vulvar cancer

5 (3.0)

92 (37.2)

97 (39.1)

Genital warts (female)

6401 (5.4)

306,673 (72.3)

313,074 (73.8)

Genital warts (male)

10,090 (2.6)

534,895 (58.2)

544,985 (59.3)

HPV 6/11-related CIN 1

20 (4.2)

894 (65.3)

914 (66.7)

Anal cancer (female)

55 (2.4)

1087 (32.2)

1142 (33.8)

Anal cancer (male)

42 (1.8)

849 (27.1)

891 (28.4)

Reduction in vaccine-preventable disease costs, % (HKD)

61,366,272 (2.1)

884,053,918 (23.2)

945,420,190 (24.8)

  1. 2vHPV 2-valent human papillomavirus, 9vHPV 9-valent human papillomavirus, CIN cervical intraepithelial neoplasia HKD Hong Kong dollars, HPV human papillomavirus
  2. aVaccine uptake was assumed to be 70%, except for the catch-up vaccination scenario, which was assessed at 30% uptake